Canaccord Genuity Rates Kymera Therapeutics (KYMR) buy

Analyst Edward Nash maintains a buy rating and sets a $129 price target for Kymera Therapeutics, a 18% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 12:01 PM EDT · Updated Jun 30, 2026, 3:11 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Kymera Therapeutics, Inc. ($KYMR) "buy" with a $129 price target on June 26, 2026.

Since the rating, $KYMR is up 6.1% after 1 week, up 1.8% after 1 month and down 3.1% to date (from the $108.12 close on Jun 26, 2026).

KYMR Kymera Therapeutics, Inc.

$104.78 +44.01% year to date

Daily close · Oct 16, 2026

Key Points

On June 26, 2026, Canaccord Genuity reiterated a buy rating on Kymera Therapeutics, Inc. with a target price of $129.
Canaccord Genuity's $129 price target implies 18% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $109.32 share price.
Kymera Therapeutics is currently trading at $109.32, down from a previous close of $117.75.
The consensus from analysts shows a strong buy recommendation with a mean target price of $138.64.

Get $KYMR trade alerts by text

We text you when insiders, Congress or big funds trade $KYMR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Kymera Therapeutics, Inc. alert may contain errors. Disclosures

Analysts Set New Price Targets

On June 26, 2026, Canaccord Genuity reiterated its buy rating on Kymera Therapeutics, Inc. (NasdaqGM: KYMR) with a target price of $129. Analyst Edward Nash believes in the company's potential despite the stock currently trading at $109.32.

Analyst rating track record

Canaccord Genuity vs. the S&P 500

YTD return -38% hypothetical

All-time return +0.67% S&P 500 +36.78%

vs. S&P 500 -36.11% behind the index

Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.

How This Rating Compares to Peers

No other funds were reported making changes to their positions in Kymera Therapeutics.

How Kymera Therapeutics, Inc. Stock Has Traded

Kymera Therapeutics is trading at $109.32, significantly below its 52-week high of $130.05. The stock has seen fluctuations but remains well above its 52-week low of $50.35. This recent rating comes after a previous close of $117.75, indicating potential volatility in the short term.

12-month forecast

$KYMR price target

Kymera Therapeutics, Inc. daily closes and this analyst's $129 target. Not advice.

Recent Earnings

The company reported revenue of $105 million, reflecting a growth of approximately 4.66%. With a negative EPS of $3.25, the company is still in the early stages of its clinical developments. The next earnings report is scheduled for November 3, 2026.

What Kymera Therapeutics, Inc. Does

Kymera Therapeutics focuses on developing small molecule drugs that target disease-causing proteins. Their research includes treatments for conditions like atopic dermatitis and various autoimmune diseases, making the analyst's positive outlook particularly relevant as they advance in clinical trials.

What to Watch at Kymera Therapeutics, Inc.

Investors should keep an eye on the upcoming earnings report in November, as well as any further analyst ratings or changes in market sentiment regarding Kymera Therapeutics. This reiteration from Canaccord Genuity reflects the firm's confidence in the company's potential amidst ongoing developments in its drug pipeline.